Stigmasterol, isoboldine, and β-sitosterol could target key prostate cancer-related hub genes (e.g., SRC, FGFR1, HSP90AA1); stigmasterol showed the strongest binding to HSP90AA1, and pathway analysis highlighted involvement of PI3K/AKT signaling. This evidence concerns the gene SRC and prostate carcinoma.